Recent findings from a real-world clinical study underscore how EPI supports clinical decision making and motivate sometimes unwilling patients to proceed to or defer prostate biopsy. In addition, this tool was proven to detect more high-grade prostate cancers over standard of care parameters alone.

Learning objectives:

• Address practical challenges in prostate cancer risk assessment and need for new tools

• Discuss patient motivators and compliance challenges to physician’s recommendation

• Highlight clinical utility in a real-world urology practice setting with a focus on the physician-patient shared decision making

• Evaluate performance of the ExoDx Prostate risk assessment test with standard of care parameters, such as PSA and widely used risk calculators.

About our Speaker: Liam J. Hurley, MD, FACS, is a urologist with Northeast Urologic Surgery PC in North Andover and Haverhill, Massachusetts, and Salem, New Hampshire. Dr. Hurley holds hospital privileges at Tufts New England Medical Center and Lahey Clinic. In 2016, he joined Imagin Medical’s Scientific Board of Advisors. His career accomplishments include launching The Boston Urologic Society, serving on the Executive Committee for the Massachusetts Association of Practicing Urologists, and presiding as the Eastern Massachusetts representative to the New England Section of the AUA.